Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant To Push Drug Eluting Stent Program In 2005

This article was originally published in The Pink Sheet Daily

Executive Summary

Cordis/Guidant drug-eluting stent technology integration slows as Cordis addresses FDA warning letter citing regulatory, quality issues. Champion DES fracture issue solved, Guidant says; redesigned Champion premarket filings to occur in first quarter next year.

You may also be interested in...



Combination Product Firms Should Follow Specialty Pharma Model, Angiotech CEO Says

CEO Hunter says Angiotech will follow specialty pharma model of risk, lifecycle management to achieve lasting success. The company also has started a venture capital unit and plans to vertically integrate its business.

Conor Set To Enroll Pivotal U.S. Study For CoStar Drug-Eluting Stent

The company will begin enrollment of a 1,700-patient U.S. pivotal trial in coming weeks. Conor is touting the paclitaxel-eluting stent as unique because it incorporates hundreds of small holes that act as reservoirs, which can be loaded with a drug-polymer combination for more controlled release over time.

Taxus Companies Clash With Conor Over European Paclitaxel Patent

Boston Scientific's suit against Conor Medsystems over paclitaxel will draw from a $75 mil. legal reserve established by the Taxus manufacturer in 2004. Angiotech is joining Boston Scientific in suing Conor over the CoStar drug-eluting stent, seeking to halt use of clinical trial data, potential sales.

Topics

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel